These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 29414253)
1. Recombinant Poliovirus for Cancer Immunotherapy. Gromeier M; Nair SK Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253 [TBL] [Abstract][Full Text] [Related]
2. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. Walton RW; Brown MC; Sacco MT; Gromeier M J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212 [TBL] [Abstract][Full Text] [Related]
3. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. Brown MC; Gromeier M Discov Med; 2015 May; 19(106):359-65. PubMed ID: 26105699 [TBL] [Abstract][Full Text] [Related]
6. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Chandramohan V; Bryant JD; Piao H; Keir ST; Lipp ES; Lefaivre M; Perkinson K; Bigner DD; Gromeier M; McLendon RE Arch Pathol Lab Med; 2017 Dec; 141(12):1697-1704. PubMed ID: 28829151 [TBL] [Abstract][Full Text] [Related]
13. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? Chiocca EA; Nassiri F; Wang J; Peruzzi P; Zadeh G Neuro Oncol; 2019 Jan; 21(1):14-25. PubMed ID: 30346600 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo. Toyoda H; Wimmer E; Cello J Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928 [TBL] [Abstract][Full Text] [Related]
15. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Toyoda H; Yin J; Mueller S; Wimmer E; Cello J Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609 [TBL] [Abstract][Full Text] [Related]
17. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Rajani KR; Vile RG Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]
19. Integrating oncolytic viruses in combination cancer immunotherapy. Bommareddy PK; Shettigar M; Kaufman HL Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717 [TBL] [Abstract][Full Text] [Related]
20. Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS. Yang Y; Brown MC; Zhang G; Stevenson K; Mohme M; Kornahrens R; Bigner DD; Ashley DM; López GY; Gromeier M Neuro Oncol; 2023 Sep; 25(9):1631-1643. PubMed ID: 36864784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]